{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T03:32:43Z","timestamp":1771471963537,"version":"3.50.1"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2023,5,30]],"date-time":"2023-05-30T00:00:00Z","timestamp":1685404800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"DOI":"10.1002\/ejhf.2890","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T06:14:35Z","timestamp":1684217675000},"page":"854-856","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Implementing Clinical Pathways to Enable Early Diagnosis and Treatment of Wild-Type Transthyretin Amyloid Cardiomyopathy"],"prefix":"10.1093","volume":"25","author":[{"given":"Steven A.","family":"Muller","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]},{"name":"Netherlands Heart Institute , Utrecht ,","place":["The Netherlands"]},{"name":"Member of the European Reference Network for rare, low prevalence and complex diseases of the Heart (ERN GUARD-Heart) , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3166-518X","authenticated-orcid":false,"given":"Marish I.F.J.","family":"Oerlemans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Utrecht , Utrecht ,","place":["The Netherlands"]},{"name":"Member of the European Reference Network for rare, low prevalence and complex diseases of the Heart (ERN GUARD-Heart) , Amsterdam ,","place":["The Netherlands"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,5,30]]},"reference":[{"key":"2026010913091750500_ejhf2890-bib-0001","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026010913091750500_ejhf2890-bib-0002","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: A systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913091750500_ejhf2890-bib-0003","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913091750500_ejhf2890-bib-0004","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026010913091750500_ejhf2890-bib-0005","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s12471-019-1299-1","article-title":"Cardiac amyloidosis: The need for early diagnosis","volume":"27","author":"Oerlemans","year":"2019","journal-title":"Neth Heart J"},{"key":"2026010913091750500_ejhf2890-bib-0006","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026010913091750500_ejhf2890-bib-0007","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: Results from phase 2 of the AC-TIVE study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913091750500_ejhf2890-bib-0008","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1002\/ejhf.2616","article-title":"Value of the HFA-PEFF and H2FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026010913091750500_ejhf2890-bib-0009","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ejhf.2823","article-title":"Diagnostic pathways to wild-type transthyretin amyloid cardiomyopathy: A multicentre network study","volume":"25","author":"Tini","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026010913091750500_ejhf2890-bib-0010","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.768847","article-title":"Automatic identification of patients with unexplained left ventricular hypertrophy in electronic health record data to improve targeted treatment and family screening","volume":"9","author":"Sammani","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026010913091750500_ejhf2890-bib-0011","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1038\/s41467-021-22876-9","article-title":"A machine learning model for identifying patients at risk for wild-type transthyretin amyloid cardiomyopathy","volume":"12","author":"Huda","year":"2021","journal-title":"Nat Commun"},{"key":"2026010913091750500_ejhf2890-bib-0012","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oeac011","article-title":"Evaluation of the cardiac amyloidosis clinical pathway implementation: A real-world experience","volume":"2","author":"Brons","year":"2022","journal-title":"Eur Heart J Open"},{"key":"2026010913091750500_ejhf2890-bib-0013","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1080\/00015385.2021.1976450","article-title":"Trends in diagnosis, referral, red flag onset, patient profiles and natural outcome of de novo cardiac amyloidosis and their multidisciplinary implications","volume":"77","author":"Debonnaire","year":"2022","journal-title":"Acta Cardiol"},{"key":"2026010913091750500_ejhf2890-bib-0014","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1002\/ehf2.13961","article-title":"Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries","volume":"9","author":"Lauppe","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026010913091750500_ejhf2890-bib-0015","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jaccao.2022.07.007","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026010913091750500_ejhf2890-bib-0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2022.101358","article-title":"Impact of tafamidis on survival in a real-world community-based cohort","volume":"47","author":"Hussain","year":"2022","journal-title":"Curr Probl Cardiol"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/6\/854\/65494099\/eurjhf_25_6_854.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/25\/6\/854\/65494099\/eurjhf_25_6_854.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:11:21Z","timestamp":1767982281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/25\/6\/854\/8341796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,30]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,5,30]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ejhf.2890","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,5,30]]},"assertion":[{"value":"2023-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}